LeBlanc et al., 20131717 LeBlanc JK, Rawl S, Juan M, Johnson C, Kroenke K, McHenry L, et al. Endoscopic ultrasound-guided celiac plexus neurolysis in pancreatic cancer: a prospective pilot study of safety using 10 mL versus 20 mL alcohol. Diagn Ther Endosc 2013;2013:327036.
|
10 |
5/5 |
66+14 |
Pancreatic cancerrelated pain |
10 mL alcohol during EUS-CPN |
- |
- |
8 |
- |
|
3 |
Gunaratnam et al., |
20011818 Gunaratnam NT, Sarma AV, Norton ID, Wiersema MJ. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc 2001;54(3):316-24.
|
58 |
32/26 |
67.1+9.3 |
Pancreatic cancer |
EUS-CPN |
- |
- |
45 |
- |
Procedure-related transient abdominal pain (5 patients) |
3 |
LeBlanc et al., 20111919 LeBlanc JK, Al-Haddad M, McHenry L, Sherman S, Juan M, McGreevy K, et al. A prospective, randomized study of EUS-guided celiac plexus neurolysis for pancreatic cancer: one injection or two? Gastrointest Endosc 2011;74(6):1300-7.
|
50 |
24/26 |
63 |
Pancreatic cancer related pain |
alcohol given as 1 vs. 2 injections during EUS-CPN |
- |
- |
37 |
4 |
There were no longterm complications |
3, 4 |
Wiechowska-Kozłowska et al., 20122020 Wiechowska-Kozlowska A, Boer K, Wójcicki M, Milkiewicz P. The efficacy and safety of endoscopic ultrasound-guided celiac plexus neurolysis for treatment of pain in patients with pancreatic cancer. Gastroenterol Res Pract 2012;2012:503098.
|
29 |
- |
- |
Advanced and unresectable pancreatic cancer |
EUS-CPN |
- |
- |
25 |
4 |
Hypotonia (1 patient), severe pain immediately post-procedure (2 patients), short episodes of diarrhea (3 patients) |
3, 4, 5 |
Hao et al., 20142121 Si-Jie H, Wei-Jia X, Yang D, Lie Y, Feng Y, Yong-Jian J, et al. How to improve the efficacy of endoscopic ultrasound-guided celiac plexus neurolysis in pain management in patients with pancreatic cancer: analysis in a single center. Surg Laparosc Endosc Percutan Tech 2014;24(1):31-5.
|
41 |
24/17 |
|
Unresectable pancreatic cancer |
EUS-CPN |
- |
- |
23 |
4 |
Transient hypotension (2 patients) |
3, 4, 5 |
Sanders et al., 20102222 Sanders MK, Moser AJ, Khalid A, Fasanella KE, Zeh HJ, Burton S, et al. EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointest Endosc 2010;71(7):1178-84.
|
51 |
29/22 |
73 |
Either locally advanced or recurrent pancreatic cancer |
EUS-SBRT |
46 |
4 |
- |
- |
Mild pancreatitis (1 patient), simultaneous placement of fiducials and celiac plexus neurolysis for intractable abdominal pain (1 patient) |
1, 2, 5 |
Sun et al., 20122323 Sun S, Ge N, Wang S, Liu X, Wang G, Guo J. Pilot trial of endoscopic ultrasound-guided interstitial chemoradiation of UICC-T4 pancreatic cancer. Endosc Ultrasound 2012;1(1):41-7.
|
8 |
3/5 |
69 |
Advanced pancreatic cancer |
(EUS-ICR) |
4 |
- |
- |
- |
- |
1 |
Figueiredo et al., 20212424 Figueiredo M, Bouchart C, Moretti L, Mans L, Engelholm JL, Bali MA, et al. EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score. Endosc Int Open 2021;9(2):E253-e7.
|
37 |
20/17 |
60 |
Borderline resectable/locally advanced pancreatic ductal adenocarcinoma |
EUS-SBRT |
34 |
3 |
- |
- |
Three patients (8 %) had adverse events (fever, mild acute pancreatitis, and biliary stent migration)" |
1, 2, 5 |
Park et al., 20102525 Park WG, Yan BM, Schellenberg D, Kim J, Chang DT, Koong A, et al. EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointest Endosc 2010;71(3):513-8.
|
57 |
29/28 |
67 ± 12 |
Locally advanced unresectable pancreatic adenocarcinoma |
EUS-guided insertion of gold fiducials |
50 |
3 |
- |
- |
3 patients |
1, 2, 5 |
Sun et al., 20062626 Sun S, Xu H, Xin J, Liu J, Guo Q, Li S. Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial. Endoscopy 2006;38(4):399-403.
|
15 |
8/7 |
61 |
Locally advanced pancreatic cancer |
EUS-guided interstitial brachytherapy |
12 |
- |
- |
- |
Pancreatitis and pseudocyst formation (3 patients); grade III hematologic toxicity (3 patients) |
1, 5 |
Bang et al., 20192727 Bang JY, Sutton B, Hawes RH, Varadarajulu S. EUS-guided celiac ganglion radiofrequency ablation versus celiac plexus neurolysis for palliation of pain in pancreatic cancer: a randomized controlled trial (with videos). Gastrointest Endosc 2019;89(1). 58-66.e3.
|
12 |
5/7 |
62.8+13.7 |
Pancreatic cancer |
EUS-RFA |
12 |
- |
- |
- |
5 patients |
5 |
Crino etal., 20182828 Crino SF, D’Onofrio M, Bernardoni L, Frulloni L, Iannelli M, Malleo G, et al. EUS-guided radiofrequency ablation (EUS-RFA) of solid pancreatic neoplasm using an 18-gauge needle electrode: feasibility, safety, and technical success. J Gastrointestin Liver Dis 2018;27(1):67-72.
|
8 |
3 (5) |
67.75 |
Pancreatic adenocarcinoma |
EUS-RFA was performed using 18-gauge internally cooled electrode with a 5- or 10-mm exposed tip |
8 |
- |
- |
- |
Mild post-procedural abdominal pain (3 patients) |
5 |
Song et al., 20162929 Song TJ, Seo DW, Lakhtakia S, Reddy N, Oh DW, Park DH, et al. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc 2016;83(2):440-3.
|
6 |
1/5 |
62 |
Unresectable pancreatic cancer |
EUS-RFA |
6 |
- |
- |
- |
Mild abdominal pain (2 patients) |
5 |